Fig. 5

Testing of Serpin-loaded EV activity in vivo. a In vivo strategy to transduce cells infiltrating PVA sponge implants and enrich their EVs for assessment of wound closure activity following the expression, release and enrichment of EVs loaded with SERPINA1, SERPINF2, SERPING1, and empty vector controls. b-d Validation of Serpin expression in engineered EVs by immunoblotting EVs recovered from implants, with densitometric quantification shown on the blot. e Quantification of wound closure kinetics following adoptive transfer in the db/db mouse model of impaired wound healing. (2-way ANOVA, p-value < 0.0001 for SERPINA1 and SERPIN G1 vs. empty vector control, n = 6 in each arm) f Representative images of splinted wounds treated with Serpin-loaded EVs. Statical analysis of wound closure efficiency in vivo using SERPINA1-EVs, SERPINF2-EVs, and SERPING1-EVs on g Day 3, h Day 5, i Day 7, j Day 10, and k Day 14 (p-value:**** < 0.0001, *** < 0.001, ** < 0.005, * < 0.05). l Representative images of immunostaining at each time point to demonstrate expression of cytokeratin 14 at Day 5 and 10 post-injury. Statistical analysis of cytokeratin staining is shown in Fig. S7